News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,963 Results
Type
Article (42549)
Company Profile (296)
Press Release (677118)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210478)
Career Advice (2093)
Deals (36635)
Drug Delivery (107)
Drug Development (83068)
Employer Resources (175)
FDA (16587)
Job Trends (15417)
News (356122)
Policy (33936)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51450)
ALS (100)
Alzheimer's disease (1405)
Antibody-drug conjugate (ADC) (141)
Approvals (16585)
Artificial intelligence (281)
Autoimmune disease (24)
Automation (17)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (190)
Bladder cancer (80)
Brain cancer (29)
Breast cancer (296)
Cancer (2367)
Cardiovascular disease (189)
Career advice (1754)
Career pathing (31)
CAR-T (161)
Cell therapy (451)
Cervical cancer (20)
Clinical research (67661)
Collaboration (884)
Company closure (2)
Compensation (579)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (260)
Cystic fibrosis (106)
Data (2364)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6468)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (125)
Drug pricing (119)
Drug shortages (28)
Duchenne muscular dystrophy (99)
Earnings (88844)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115584)
Executive appointments (763)
FDA (17999)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (788)
Gene editing (116)
Generative AI (22)
Gene therapy (335)
GLP-1 (761)
Government (4557)
Grass and pollen (5)
Guidances (167)
Healthcare (19004)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (135)
Indications (30)
Infectious disease (2809)
Inflammatory bowel disease (147)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (101)
Interviews (323)
IPO (16808)
IRA (47)
Job creations (4060)
Job search strategy (1493)
Kidney cancer (10)
Labor market (43)
Layoffs (500)
Leadership (18)
Legal (8380)
Liver cancer (77)
Lung cancer (327)
Lymphoma (161)
Machine learning (9)
Management (59)
Manufacturing (345)
MASH (80)
Medical device (13475)
Medtech (13480)
Mergers & acquisitions (20404)
Metabolic disorders (734)
Multiple sclerosis (83)
NASH (17)
Neurodegenerative disease (99)
Neuropsychiatric disorders (29)
Neuroscience (1990)
NextGen: Class of 2025 (6638)
Non-profit (4528)
Now hiring (40)
Obesity (387)
Opinion (230)
Ovarian cancer (82)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (156)
Partnered (22)
Patents (251)
Patient recruitment (117)
Peanut (49)
People (59342)
Pharmaceutical (91)
Pharmacy benefit managers (22)
Phase I (20994)
Phase II (29777)
Phase III (22300)
Pipeline (1438)
Policy (161)
Postmarket research (2654)
Preclinical (8949)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (406)
Real estate (6258)
Recruiting (67)
Regulatory (23200)
Reports (48)
Research institute (2370)
Resumes & cover letters (358)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (80)
Series A (136)
Series B (92)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3730)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (56)
The Weekly (50)
Vaccines (720)
Venture capitalists (42)
Weight loss (256)
Women's health (36)
Worklife (16)
Date
Today (183)
Last 7 days (1023)
Last 30 days (3377)
Last 365 days (33057)
2025 (12299)
2024 (35772)
2023 (40630)
2022 (51797)
2021 (56330)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32517)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40776)
Australia (6532)
California (6516)
Canada (2089)
China (556)
Colorado (278)
Connecticut (283)
Delaware (162)
Europe (87145)
Florida (967)
Georgia (217)
Idaho (57)
Illinois (563)
India (26)
Indiana (332)
Iowa (11)
Japan (177)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (934)
Massachusetts (4874)
Michigan (228)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1818)
New Mexico (29)
New York (1831)
North Carolina (1013)
North Dakota (8)
Northern California (2877)
Ohio (210)
Oklahoma (14)
Oregon (39)
Pennsylvania (1449)
Puerto Rico (13)
Rhode Island (33)
South America (1163)
South Carolina (26)
South Dakota (1)
Southern California (2446)
Tennessee (107)
Texas (969)
United States (24452)
Utah (190)
Virginia (163)
Washington D.C. (64)
Washington State (577)
West Virginia (3)
Wisconsin (61)
719,963 Results for "ultragenyx pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide catch up?
March 17, 2025
·
3 min read
·
Jia Jie Chen
Press Releases
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
May 8, 2025
·
1 min read
Press Releases
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
May 7, 2025
·
13 min read
Press Releases
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
April 30, 2025
·
1 min read
Press Releases
Ultragenyx to Participate at Investor Conferences in March
February 24, 2025
·
1 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 22, 2025
April 23, 2025
·
1 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 19, 2025
March 20, 2025
·
1 min read
Press Releases
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
February 14, 2025
·
15 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 20, 2024
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 45,525 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company.
June 20, 2024
·
1 min read
Biotech Bay
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 17, 2024
Ultragenyx Pharmaceutical Inc. reported the grant of 17,180 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company.
May 17, 2024
·
1 min read
1 of 71,997
Next
